Description
OMNIA 2.5 mg is a medication manufactured by Incepta Pharmaceuticals Ltd., containing mavacamten, which is used for treating obstructive hypertrophic cardiomyopathy (HCM) in adults, particularly those with symptomatic New York Heart Association (NYHA) class II–III. Mavacamten works by inhibiting excessive cardiac muscle contractility, which helps reduce left ventricular outflow tract obstruction and improves symptoms such as shortness of breath and fatigue. The usual starting dose is 2.5 mg once daily, with the possibility of dosage adjustment based on the patient's response. Common side effects may include headache, dizziness, and fatigue. The medication should be taken under medical supervision, ensuring proper monitoring for any adverse effects.
.png)
.jpeg)
 100 IU 3 ML.webp)
.webp)
 400MG.jpg)
.jpg)
.jpeg)
.jpg)
.jpg)
.webp)
.jpg)
.jpg)
.jpg)
.webp)
.jpg)
.jpg)
.jpeg)
.jpeg)
Change Language